Sequenom Announces Key Milestone In Development Of Noninvasive Prenatal Down Syndrome Test

Sequenom, Inc. (NASDAQ:SQNM) announced a significant step in the development of a noninvasive test for Trisomy 21, Down syndrome, that will incorporate multiple RNA fetal markers, including the PLAC4 gene as previously published by Dr. Dennis Lo, Chinese Hong Kong University. In preliminary studies, more than 100 clinical plasma specimens of various ethnicities were tested with partners using the Company’s MassARRAY® platform and its SEQureDx? Technology.

More: continued here

Filed under: Pregnancy on February 26th, 2008